In the present report, the role of ATR-Chk1-Wee1 and ATM-Chk2-p53-p21 pathways in stress-induced cell cycle control is analysed in melanoma cells. Treatment of p53 wild-type melanoma cells with the genotoxic agent doxorubicin induces G2-M arrest, inhibitory phosphorylation of cell cycle kinase Cdc2 (CDK1) and enhanced expression of p53/p21. Wee1 inhibition under doxorubicin pulse-treatment reduces G2-M arrest and induces apoptosis. Inhibition of upstream kinase Chk1 under doxorubicin treatment almost completely abolishes stress-induced G2-M arrest and induces enhanced apoptosis. Interestingly, Chk1 inhibition alone even further increases apoptosis. While Chk1 inhibition alone almost completely abolishes G0-G1 arrest, combined treatment with doxorubicin re-establishes G0-G1 arrest. Moreover, Chk1 inhibition alone induces only a slight p53/p21 induction, while a strong induction of both proteins is observed by the combination with doxorubicin. These findings are suggestive for a particular role of p53/p21 in G0-G1, and Chkl in G0-G1 and G2-M arrest. In line with this, the p53-mutant SK-Mel-28 melanoma cells do not mount a significant G0-G1 arrest under combined doxorubicin and Chkl inhibitor treatment but rather show extensive apoptosis. Moreover, knockdown of p21 dramatically reduces stress-induced G0-G1 arrest under doxorubicin and Chkl inhibitor treatment accompanied by massive DNA damage and apoptosis induction. Treatment of melanoma cells with an inhibitor of Chk2 upstream kinase ATM and doxorubicin almost completely abolishes G0-G1 arrest. Taken together, both Chk1 and Wee1 are mediators of G2-M arrest, while p53, p21 and Chkl are mediators of G0-G1 arrest in melanoma cells. Combined treatment with chemotherapeutic agents such as doxorubicin and Chk1 inhibitors may help to overcome apoptosis resistance of p53-proficient melanoma cells. But treatment with Chkl inhibitor alone may even be more efficient. (C) 2015 Elsevier Inc All rights reserved.
机构:
Calvary Mater Newcastle Hosp, Immunol & Oncol Unit, Newcastle, NSW, AustraliaCalvary Mater Newcastle Hosp, Immunol & Oncol Unit, Newcastle, NSW, Australia
Hersey, P.
;
Bastholt, L.
论文数: 0引用数: 0
h-index: 0
机构:
Odense Univ Hosp, Dept Oncol, DK-5000 Odense, DenmarkCalvary Mater Newcastle Hosp, Immunol & Oncol Unit, Newcastle, NSW, Australia
Bastholt, L.
;
Chiarion-Sileni, V.
论文数: 0引用数: 0
h-index: 0
机构:
Ist Oncol Veneto, Dept Oncol, Padua, ItalyCalvary Mater Newcastle Hosp, Immunol & Oncol Unit, Newcastle, NSW, Australia
Chiarion-Sileni, V.
;
Cinat, G.
论文数: 0引用数: 0
h-index: 0
机构:
Inst Oncol Angel Roffo, Dept Oncol, Buenos Aires, DF, ArgentinaCalvary Mater Newcastle Hosp, Immunol & Oncol Unit, Newcastle, NSW, Australia
Cinat, G.
;
Dummer, R.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, SwitzerlandCalvary Mater Newcastle Hosp, Immunol & Oncol Unit, Newcastle, NSW, Australia
Dummer, R.
;
Eggermont, A. M. M.
论文数: 0引用数: 0
h-index: 0
机构:
Erasmus Univ, Med Ctr, Dr Daniel Den Hoed Canc Ctr, Dept Surg Oncol, Rotterdam, NetherlandsCalvary Mater Newcastle Hosp, Immunol & Oncol Unit, Newcastle, NSW, Australia
Eggermont, A. M. M.
;
Espinosa, E.
论文数: 0引用数: 0
h-index: 0
机构:
Hosp La Paz, Dept Oncol, Madrid, SpainCalvary Mater Newcastle Hosp, Immunol & Oncol Unit, Newcastle, NSW, Australia
Espinosa, E.
;
Hauschild, A.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Kiel, Dept Dermatol, D-2300 Kiel, GermanyCalvary Mater Newcastle Hosp, Immunol & Oncol Unit, Newcastle, NSW, Australia
Hauschild, A.
;
Quirt, I.
论文数: 0引用数: 0
h-index: 0
机构:
Princess Margaret Hosp, Toronto, ON M4X 1K9, CanadaCalvary Mater Newcastle Hosp, Immunol & Oncol Unit, Newcastle, NSW, Australia
Quirt, I.
;
Robert, C.
论文数: 0引用数: 0
h-index: 0
机构:
Inst Gustave Roussy, Dept Dermatol, Villejuif, FranceCalvary Mater Newcastle Hosp, Immunol & Oncol Unit, Newcastle, NSW, Australia
Robert, C.
;
Schadendorf, D.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Hosp Essen, Dept Dermatol, Essen, GermanyCalvary Mater Newcastle Hosp, Immunol & Oncol Unit, Newcastle, NSW, Australia
机构:
Calvary Mater Newcastle Hosp, Immunol & Oncol Unit, Newcastle, NSW, AustraliaCalvary Mater Newcastle Hosp, Immunol & Oncol Unit, Newcastle, NSW, Australia
Hersey, P.
;
Bastholt, L.
论文数: 0引用数: 0
h-index: 0
机构:
Odense Univ Hosp, Dept Oncol, DK-5000 Odense, DenmarkCalvary Mater Newcastle Hosp, Immunol & Oncol Unit, Newcastle, NSW, Australia
Bastholt, L.
;
Chiarion-Sileni, V.
论文数: 0引用数: 0
h-index: 0
机构:
Ist Oncol Veneto, Dept Oncol, Padua, ItalyCalvary Mater Newcastle Hosp, Immunol & Oncol Unit, Newcastle, NSW, Australia
Chiarion-Sileni, V.
;
Cinat, G.
论文数: 0引用数: 0
h-index: 0
机构:
Inst Oncol Angel Roffo, Dept Oncol, Buenos Aires, DF, ArgentinaCalvary Mater Newcastle Hosp, Immunol & Oncol Unit, Newcastle, NSW, Australia
Cinat, G.
;
Dummer, R.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, SwitzerlandCalvary Mater Newcastle Hosp, Immunol & Oncol Unit, Newcastle, NSW, Australia
Dummer, R.
;
Eggermont, A. M. M.
论文数: 0引用数: 0
h-index: 0
机构:
Erasmus Univ, Med Ctr, Dr Daniel Den Hoed Canc Ctr, Dept Surg Oncol, Rotterdam, NetherlandsCalvary Mater Newcastle Hosp, Immunol & Oncol Unit, Newcastle, NSW, Australia
Eggermont, A. M. M.
;
Espinosa, E.
论文数: 0引用数: 0
h-index: 0
机构:
Hosp La Paz, Dept Oncol, Madrid, SpainCalvary Mater Newcastle Hosp, Immunol & Oncol Unit, Newcastle, NSW, Australia
Espinosa, E.
;
Hauschild, A.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Kiel, Dept Dermatol, D-2300 Kiel, GermanyCalvary Mater Newcastle Hosp, Immunol & Oncol Unit, Newcastle, NSW, Australia
Hauschild, A.
;
Quirt, I.
论文数: 0引用数: 0
h-index: 0
机构:
Princess Margaret Hosp, Toronto, ON M4X 1K9, CanadaCalvary Mater Newcastle Hosp, Immunol & Oncol Unit, Newcastle, NSW, Australia
Quirt, I.
;
Robert, C.
论文数: 0引用数: 0
h-index: 0
机构:
Inst Gustave Roussy, Dept Dermatol, Villejuif, FranceCalvary Mater Newcastle Hosp, Immunol & Oncol Unit, Newcastle, NSW, Australia
Robert, C.
;
Schadendorf, D.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Hosp Essen, Dept Dermatol, Essen, GermanyCalvary Mater Newcastle Hosp, Immunol & Oncol Unit, Newcastle, NSW, Australia